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I n 2018,  there were an estimated 403,000 new cases of kidney cancer worldwide [1].  Renal cell carci-
noma (RCC) accounts for 3% of all malignancies,  and 
over the last two decades the annual incidence of RCC 
has increased by 2% [2].  The majority of RCCs occur 
sporadically,  but 2-4% of all RCC cases are known to 
have a heritable basis,  for example,  von Hippel-Lindau 
disease (VHL) [3].  VHL is the most common heredi-
tary renal cancer syndrome,  occurring in approx.  1 of 
every 36,000 births [4 , 5].  It is an autosomal dominant 
inherited syndrome caused by germline mutations in 
the VHL tumor suppressor gene.  VHL is characterized 
by tumors in multiple organs: e.g.,  retinal and central 
nerve system (CNS) hemangioblastomas,  pheochro-
mocytomas,  pancreatic neuroendocrine tumors,  and 
multiple clear-cell RCC [6 , 7].
RCC is the most common cancer that develops in 
individuals with VHL; approx.  40% of individuals with 
VHL have multifocal,  bilateral RCC,  and the lesions 
will be solid,  cystic,  or both [8].  The reported average 
life expectancy in patients with VHL is roughly 50 years 
because of a high prevalence and recurrence rate of RCC 
[3].  RCC is the major cause of death in patients with 
VHL.  One report demonstrated that nearly 30% of 
patients with VHL died due to RCC [9].  The manage-
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ment of RCC in patients with VHL is thus very import-
ant.
Historically,  the surgical treatment options for RCC 
are radical nephrectomy and partial nephrectomy (PN).  
More recently,  ablative techniques including radiofre-
quency ablation (RFA) and cryoablation (CA) became 
valid alternatives to nephron-sparing surgery via a min-
imally invasive approach.  CA was approved by Japan’s 
national health insurance system in 2011 at the limited 
number of institutions.  The modality used for CA is 
either percutaneous or laparoscopic.
Percutaneous CA has been preferred in Japan because 
of its lower cost,  shorter procedure time,  and lesser 
invasiveness than laparoscopic CA (‘lap CA’).  Lap CA 
requires the use of many disposable devices such as lap-
aroscopic ports.  Percutaneous hydrodissection is some-
times used to separate tumors and important organs in 
order to prevent injury [10].  In some cases however,  a 
safety margin between the tumor and an organ cannot 
be achieved even with hydrodissection [11].  Lap CA is 
useful in these cases since important organs can be pro-
tected laparoscopically.  To our knowledge,  the present 
case report is the first to describe combined laparo-
scopic and computed tomography (CT) monitoring of 
ice-ball formation and its precise margin during 
cryoablation for renal cell carcinoma.
Case Report
A 47-year-old Japanese female was referred to our 
institution for the treatment of bilateral multiple RCC 
associated with VHL.  She had undergone 10 prior 
treatments for bilateral multiple RCC.  Briefly,  her 
treatment had begun with left PNs performed 18 and 21 
years earlier at another hospital.  The 2nd PN was for 
local recurrence.  She was then referred to our interven-
tional radiologist.  She had undergone two percutane-
ous RFAs for two right RCCs 11 years earlier,  and four 
percutaneous CA for 6 different left tumors and one 
right tumor 1 , 2 , 4 and 7 years prior to her referral.  Two 
of the lesions had been treated by transcatheter arterial 
embolization (TAE) using the mixture of ethanol and 
iodized oil (Lipiodol,  Guerbet,  Villepinte,  France):  
one on the right 2 years ago and the other on the left 1 
year ago.  The left lesion was very small,  and it was dif-
ficult to perform cryoablation of the right lesion due to 
the tumor’s location.  Thus,  ablation therapy was not 
applied to those lesions,  which were then observed 
carefully.
Twenty-one years after the patient’s first diagnosis of 
RCC,  CT revealed the enlarged lesion in the lower pole 
of the right kidney,  which was considered the recur-
rence of the RCC after the TAE (Fig. 1A).  The tumor 
had grown from 10 mm to 14 mm in 2 years.  The 
tumor was attached to the right ureter.  A safety margin 
between the tumor and the ureter could not have been 
achieved even with hydrodissection during the percuta-
neous technique.  Therefore,  lap CA was deemed safer 
and the patient was referred to us by our interventional 
radiologist.
Her medical history was significant for cerebellar 
hemangioblastoma,  and uterine myoma.  She was tak-
ing no medications.  Her father and younger brother 
also had VHL.  Laboratory test results were normal.  
Her serum creatinine (Cr) level was 0.77 mg/dL.  The 
treatment options were thoroughly discussed with the 
patient,  including percutaneous CA,  lap CA,  robot-as-
sisted PN (RAPN),  and radical nephrectomy.  The 
patient selected lap CA to maximize the possibility of 
preserving renal function.
The procedure was performed in a room equipped 
with a sliding gantry CT scanner (Aquilion CX64,  
Canon Medical Systems,  Otawara,  Japan),  with the 
patient under general anesthesia in the supine position.  
First,  the right ureteral stent was placed to help identify 
the ureter.  The patient was then changed to right decu-
bitus position.  Five ports were used.  The ascending 
colon was mobilized,  and the right kidney and the 
tumor were exposed.  The right ureter was attached to 
the tumor due to the effect of the previous TAE.  Special 
care was taken to dissect the ureter to prevent ischemia 
of the ureter.  The renal artery and vein were intention-
ally not dissected; this was to avoid postoperative 
adhesion because the patient might someday require a 
PN or nephrectomy for local recurrence considering the 
nature of VHL.  CA was performed by interventional 
radiologists using an argon-based cryoablation system 
(Cryo-Hit,  Galil Medical,  Youknum,  Israel) and three 
17G cryoprobes (IceSeed,  Galil Medical) under laparo-
scopic vision.  Three cryoprobes were inserted from the 
12-mm and 5-mm laparoscopic ports.  The right ureter 
was protected by being wrapped three times with gauze 
(Fig. 2A).  CT scanning was performed before the abla-
tion to check the probe positions,  followed by adjust-
ment of the probe positions.  The ablation protocol 
included 10- to 15-min freezing cycles separated by 
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2 min of passive thawing (Fig. 2B).  Special care was also 
taken in order not to injure the ureter during the freez-
ing and thawing.  During the freezing,  the CT scan was 
repeated to confirm an ice-ball margin of ≥ 6 mm 
(Fig. 1B).
The operative time was 4 h and 15 min; the time for 
CA was 2 h and 3 min.  The estimated blood loss was 
minimal.  Good hemostasis was obtained without the 
need for parenchymal suturing,  a fibrin sealant patch,  
or fibrin glue.
The follow-up CT scan at 6 months revealed no local 
progression (Fig. 1C).  The patient’s serum Cr level has 
remained at the baseline at 0.73 mg/dL,  and the patient 
does not shown proteinuria in urinalyses.
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Fig. 2　 A,  Intraoperative image of the laparoscopic cryoablation.  Three cryoprobes were inserted from the laparoscopic ports; B,  The 
freezing phase.  Arrow: Gauze.  The right ureter was protected by being wrapped three times with gauze.
Fig. 1　 A,  Computed tomography (CT) with intravenous contrast medium 
showed the enlarged lesion (black dotted line) in the lower pole of the right 
kidney beside the lipiodol deposition (asterisk),  which was considered local 
progression of the renal cell carcinoma after the patientʼs transcatheter arte-
rial embolization.  The diameter of the right tumor was 14 mm.  The tumor 
was attached to the right ureter (arrow); B,  Plain CT at the end of the sec-
ond freeze cycle demonstrated three cryoprobes (arrows) positioned within 
the renal mass.  The ice-ball was detected as a well-demarcated region of 
hypodensity in the surrounding tissue (arrowhead); C,  CT with intravenous 
medium 6 months after laparoscopic cryoablation shows no local progression 
of the tumor.  Black dotted line: The laparoscopic cryoablation treatment area.
Discussion
We have reported a successful lap CA procedure in a 
patient with VHL who had undergone 10 treatments for 
her bilateral RCC.  The tumor could not have been 
treated with percutaneous CA due to its proximity to the 
ureter.  CT monitoring was also used to confirm the 
precise ≥ 6 mm ice-ball margin.  To our knowledge,  this 
is the first report of combined laparoscopic and CT 
monitoring of the formation of an ice-ball margin 
during cryoablation for RCC.
In patients with VHL,  several interventions includ-
ing surgical and ablative treatments are available to 
prevent disease progression and for the maintenance of 
renal function.  Matin et al.  reported that 88% of 
patients with VHL and RCC required some interven-
tions,  and 80% of the interventions were nephron- 
sparing approaches at a median follow-up of 41 
months.  The metastasis-free survival was 93% and the 
overall survival (OS) was 88% [12].
The treatment of localized RCC has shifted from 
radical nephrectomy to PN and ablative therapies over 
the years.  Ablative interventions include percutaneous 
or lap RFA/CA.  Table 1 provides an overview of the 
management strategies used for patients with localized 
RCC,  including the advantages and disadvantages of 
each approach [13].  Ablative techniques can offer a 
minimally invasive approach,  and their use helps avoid 
extirpative surgery and provides shorter hospital stays 
and faster recovery [14].  The current available guide-
lines note that ablative techniques as treatment options 
are confined to patients who are at risk of renal function 
loss (e.g.,  single kidney or genetic predisposition for 
multiple tumors) [2].
CA has become an important therapeutic option as 
a nephron-sparing modality.  The effectiveness of CA for 
treating T1a renal tumors is well established [15].  CA 
therapy is a potential treatment alternative for patients 
with T1a renal tumors that are not suitable for extirpa-
tive surgery [16].  Lap CA was introduced in 1998 [17].  
From a short-term perspective,  lap CA is associated 
with lower perioperative complications compared to 
open surgery [18 , 19].  Larcher et al.  reported that lap 
CA leads to safe long-term cancer control in patients 
who have a single T1a small renal tumor [20].  Nielsen 
et al.  reported that the rates of 5- and 10-year disease- 
free survival after lap CA were 90% and 80%,  and the 
5- and 10-year OS rates were 83% and 64%,  respec-
tively [16].
We selected lap CA for our patient because the 
tumor was too close to the right ureter.  Percutaneous 
hydrodissection is frequently used to separate a tumor 
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Table 1　 Treatments options used for localized renal cell carcinoma
Treatment Advantage(s) Disadvantage(s)
RN Effectiveness for tumors with
high complexity
Risk of surgical blood loss
Risk of adhesion after surgery
Greatest risk of decreasing GFR
RAPN Preservation of GFR
Less invasiveness than RN
Risk of surgical blood loss
Risk of adhesion after surgery
Increased risk of
urologic complications
Lap CA Minimally invasive approach
Intraoperative direct visualization
Avoidance of extirpative surgery
Better preservation of GFR than PN
Increased risk of local recurrence
Percutaneous CA Minimally invasive approach
Intraoperative real-time monitoring
Avoidance of extirpative surgery
Short procedure time
Better preservation of GFR than PN
Increased risk of local recurrence
No direct visualization during procedure
Source.  —Reference 13.
Note.  — RN,  radical nephrectomy; RAPN,  robot assisted partial nephrectomy; Lap CA,  laparoscopic cryoablation; PN,  partial nephrec-
tomy; CA,  cryoablation; GFR,  glomerular filtration rate.
and an important organ to prevent injury [10].  
However,  we speculated that hydrodissection could not 
have worked well in case because the right ureter was 
adhered firmly to the tumor due to the effect of the pre-
vious TAE treatment.  A laparoscopic lysis of the adhe-
sion was required.  We also added a step by wrapping 
the right ureter 3 times with gauze and lifting the entire 
right kidney to protect the ureter from injury during the 
freezing and thawing.
Lap CA is usually monitored by ultrasound whereas 
percutaneous CA is usually monitored by ultrasound or 
CT.  CT is more accurate for monitoring ice-ball forma-
tion and its precise margin [21].  It can be difficult to 
monitor a lap CA procedure by CT because most oper-
ation rooms are not equipped with CT.  We used CT to 
assist the lap CA procedure in the present case,  and we 
observed that unlike direct vision through laparoscopy 
and ultrasound monitoring,  CT was useful to confirm 
the ice-ball formation and its precise margin inside the 
kidney and thereby to secure complete tumor ablation.
RAPN was another option in the present case.  We 
have performed over 200 RAPNs.  RAPN was not 
selected for our present patient,  for the following two 
reasons.  (1) A systematic review and meta-analysis 
comparing CA and PN in clinical stage T1 renal masses 
demonstrated a decreased estimated glomerular filtra-
tion rate and increased Cr level [22].  The authors of that 
meta-analysis indicated that CA could preserve renal 
function significantly better compared to PN,  and they 
speculated that CA could preserve better renal function 
by being combined with laparoscopic or CT/ultrasound 
vision.  We felt that CA was more appropriate than a PN 
for our patient in light of her young age (47 years) and 
the high possibility of RCC recurrence due to the nature 
of VHL.  (2) RAPN was feasible.  Our patient’s R.E.N.A.L.  
nephrometry score (a scoring system used to assess the 
difficulty of nephron-sparing surgery [23]) was 5a,  
which indicates a low risk.  However,  RAPN requires 
renal hilum dissection and usually uses a fibrin sealant 
patch or fibrin glue for hemostasis.  These procedures 
cause adhesion around the renal hilum,  making the 
next surgery very difficult.  Considering our patient’s 
age and the high recurrence rate of VHL,  it is entirely 
possible that she could have a further recurrence and 
require multiple treatments over the rest of her life.  We 
felt that RAPN should be saved for when there are no 
other options (including CA).
The lap CA was successful without complications.  It 
was especially useful to protect the ureter.  The CT 
monitoring was also useful to confirm the precise ≥6 mm 
ice-ball margin.  At 6 months post-surgery,  renal pres-
ervation and good cancer control were confirmed after 
the minimally invasive procedure.
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